Combination Drugs taking Flow-on Price Reductions for 1 October 2018
Page last updated: 1 October 2018
The 2015 Access and Sustainability amendments to the National Health Act 1953 provide for price disclosure reductions to component drugs to be flowed-on to F2 combination items where this results in a lower price than direct application of price disclosure to the F2 combination item. This type of flow-on reduction to combination drugs on F2 is in addition to the usual flow-on of price reductions to combination drugs on the Combination Drug List (CDL).
There are no combination drugs taking price disclosure flow-on price reductions for October 2018.